Novartis Will Not Split Biosimilars From Sandoz As Part Of Review
Swiss Firm Focused On Carving Out Its Financials And Identifying Scope
Reporting Q4 and full-year earnings, Novartis told attendees to the company conference call that evaluating all options for its Sandoz business would take months yet, while making its position clear on Sandoz’ multi-billion-dollar biosimilars business.
